Palvella Therapeutics, Inc. Diluted Shares Outstanding (Weighted Average)
Palvella Therapeutics, Inc. (PVLA) reported Diluted Shares Outstanding (Weighted Average) of 14.36 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-04
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 14.36M shares, a 29.89% increase year-over-year.
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 13.09M shares, a 18.81% increase year-over-year.
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 11.87M shares, a 230.45% increase year-over-year.
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 11.06M shares, a 525.04% increase year-over-year.
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 11.25M shares, a 405.46% increase from fiscal 2024.
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 2.23M shares, a 24.08% increase from fiscal 2023.
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 1.79M shares.
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2021 was 64.55M shares, a 18.48% increase from fiscal 2020.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 14.36M shares 10-Q · filed 2026-08-04 | 13.72M shares 10-Q · filed 2026-08-04 | 13.11M shares derived: average of 3 quarters · filed 2026-08-04 | 12.59M shares derived: average of 4 quarters · filed 2026-08-04 | |||
| 2026-03-31 | 13.09M shares 10-Q · filed 2026-05-07 | 12.48M shares derived: average of 2 quarters · filed 2026-05-07 | 12.01M shares derived: average of 3 quarters · filed 2026-05-07 | 11.77M shares derived: average of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | 11.87M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 11.47M shares derived: average of 2 quarters · filed 2026-03-31 | 11.33M shares derived: average of 3 quarters · filed 2026-08-04 | 11.25M shares 10-K · filed 2026-03-31 | |||
| 2025-09-30 | 11.06M shares 10-Q · filed 2025-11-12 | 11.06M shares derived: average of 2 quarters · filed 2026-08-04 | 11.04M shares 10-Q · filed 2025-11-12 | 9.18M shares derived: average of 4 quarters · filed 2026-08-04 | |||
| 2025-06-30 | 11.05M shares 10-Q · filed 2026-08-04 | 11.03M shares 10-Q · filed 2026-08-04 | 8.55M shares derived: average of 3 quarters · filed 2026-08-04 | 6.86M shares derived: average of 4 quarters · filed 2026-08-04 | |||
| 2025-03-31 | 11.01M shares 10-Q · filed 2026-05-07 | 7.30M shares derived: average of 2 quarters · filed 2026-05-07 | 5.46M shares derived: average of 3 quarters · filed 2026-05-07 | 4.54M shares derived: average of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | 3.59M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 2.68M shares derived: average of 2 quarters · filed 2026-03-31 | 2.38M shares derived: average of 3 quarters · filed 2026-03-31 | 2.23M shares 10-K · filed 2026-03-31 | |||
| 2024-09-30 | 1.77M shares 10-Q · filed 2025-11-12 | 1.32M shares 10-Q · filed 2024-11-13 | 1.77M shares derived: average of 2 quarters · filed 2025-11-12 | 1.77M shares 10-Q · filed 2025-11-12 | 1.28M shares 10-Q · filed 2024-11-13 | 2.30M shares derived: average of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | 1.77M shares 10-Q · filed 2025-08-14 | 1.30M shares 10-Q · filed 2024-08-14 | 1.77M shares 10-Q · filed 2025-08-14 | 1.27M shares 10-Q · filed 2024-08-14 | 2.48M shares derived: average of 3 quarters · filed 2025-08-14 | 2.17M shares derived: average of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | 1.77M shares 10-Q · filed 2025-05-15 | 2.84M shares derived: average of 2 quarters · filed 2025-05-15 | 2.31M shares derived: average of 3 quarters · filed 2025-05-15 | 2.00M shares derived: average of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | 3.91M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 2.57M shares derived: average of 2 quarters · filed 2025-03-31 | 2.08M shares derived: average of 3 quarters · filed 2025-03-31 | 1.79M shares 10-K · filed 2025-03-31 | |||
| 2023-09-30 | 1.24M shares 10-Q · filed 2024-11-13 | 1.17M shares derived: average of 2 quarters · filed 2024-11-13 | 1.09M shares 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | 1.10M shares 10-Q · filed 2024-08-14 | 87.83M shares 10-Q · filed 2023-08-10 | 1.01M shares 10-Q · filed 2024-08-14 | 81.11M shares 10-Q · filed 2023-08-10 | |||
| 2022-06-30 | 74.13M shares 10-Q · filed 2023-08-10 | 73.92M shares 10-Q · filed 2023-08-10 | 73.32M shares derived: average of 3 quarters · filed 2023-08-10 | 71.92M shares derived: average of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | 73.71M shares 10-Q · filed 2022-05-11 | 72.92M shares derived: average of 2 quarters · filed 2022-05-11 | 71.19M shares derived: average of 3 quarters · filed 2022-05-11 | 68.87M shares derived: average of 4 quarters · filed 2022-08-04 | |||
| 2021-12-31 | 72.13M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | 69.93M shares derived: average of 2 quarters · filed 2022-03-02 | 67.26M shares derived: average of 3 quarters · filed 2022-08-04 | 64.55M shares 10-K · filed 2022-03-02 | |||
| 2021-09-30 | 67.73M shares 10-Q · filed 2021-11-02 | 64.82M shares derived: average of 2 quarters · filed 2022-08-04 | 62.02M shares 10-Q · filed 2021-11-02 | 60.48M shares derived: average of 4 quarters · filed 2022-08-04 | |||
| 2021-06-30 | 61.91M shares 10-Q · filed 2022-08-04 | 59.12M shares 10-Q · filed 2022-08-04 | 58.07M shares derived: average of 3 quarters · filed 2022-08-04 | 57.13M shares derived: average of 4 quarters · filed 2022-08-04 | |||
| 2021-03-31 | 56.30M shares 10-Q · filed 2022-05-11 | 56.15M shares derived: average of 2 quarters · filed 2022-05-11 | 55.54M shares derived: average of 3 quarters · filed 2022-05-11 | 54.75M shares derived: average of 4 quarters · filed 2022-05-11 | |||
| 2020-12-31 | 56.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | 55.17M shares derived: average of 2 quarters · filed 2022-03-02 | 54.24M shares derived: average of 3 quarters · filed 2022-03-02 | 54.48M shares 10-K · filed 2022-03-02 | |||
| 2020-09-30 | 54.34M shares 10-Q · filed 2021-11-02 | 53.36M shares derived: average of 2 quarters · filed 2021-11-02 | 53.98M shares 10-Q · filed 2021-11-02 | ||||
| 2020-06-30 | 52.37M shares 10-Q · filed 2021-08-05 | 53.79M shares 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |